NCT02618356Unknown2 期
A Phase II Clinical Study of Combined Use of Raltitrexed and S-1 as Treatment for Patients With Metastasizing Colorectal Cancer Failed of Standard Chemotherapy
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 82
- 试验地点
- 1
- 主要终点
- Median disease progression free survival (mPFS) of Raltitrexed combined with S-1
研究概览
简要总结
The primary endpoint is to evaluate the Median disease progression free survival (mPFS).
详细描述
The primary endpoint is to evaluate the disease progression free survival (mPFS) of Raltitrexed combined with S-1 as treatment for patients with metastasizing colorectal cancer failed of standard chemotherapy
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •≥18 years of age
- •Histologically or cytologically confirmed adenocarcinoma of the colon or rectum
- •No systemic chemotherapy for metastatic tumors
- •ECOG (Eastern Cooperative Oncology Group) 0-1 and expected survival period for 3 months or more
- •At least one measurable objective tumor lesions according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
- •ANC≥1.5*109/L；PLT≥80*109/L；HB≥90g/L；Total bilirubin ≤ 1.5 x the upper limit of normal (ULN) ; Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 x ULN (≤ 5 x ULN for subjects with liver involvement of their cancer)；ALB ≥ 30g/L; Serum creatinine ≤1.5(ULN) or glomerular filtration rate (GFR) ≥60 ml/min screening within 7 days
- •Progression during or within 3 months following the last administration of approved standard therapies which must include a fluoropyrimidine, oxaliplatin and irinotecan. Subjects treated with oxaliplatin in an adjuvant setting should have progressed during or within 6 months of completion of adjuvant therapy. Subjects who progress more than 6 months after completion of oxaliplatin containing adjuvant treatment must be retreated with oxaliplatin-based therapy to be eligible. Subjects who have withdrawn from standard treatment due to unacceptable toxicity warranting discontinuation of treatment and precluding retreatment with the same agent prior to progression of disease will also be allowed into the study. Subjects may have received prior treatment with Avastin (bevacizumab) and/or Erbitux (cetuximab)/Vectibix (panitumumab) (if KRAS WT)
- •Signed informed consent obtained before any study specific procedures. Subjects must be able to understand and willing to sign a written informed consent.
排除标准
- •Prior treatment with raltitrexed and gimeracil and oteracil potassium
- •Systemic anticancer therapy including cytotoxic therapy, signal transduction inhibitors, immunotherapy and hormonal therapy during this trial or within 4 weeks (or 6 weeks for mitomycin C) before starting to receive study medication.
- •Alcohol or drug addictions
- •Previous or concurrent cancer that is distinct in primary site or histology from colorectal cancer within 5 years prior to randomization EXCEPT for curatively treated cervical cancer in situ, non-melanoma skin cancer and superficial bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ) and T1 (tumor invades lamina propria)]
- •Any history of or currently known brain metastases
- •Multiple primary colorectal carcinoma
- •Concomitant participation or participation within the last 30 days in another clinical trial
- •There is an important organ failure or other serious diseases, including coronary artery disease, symptomatic cardiovascular disease or myocardial infarction within 12 months; serious neurological or psychiatric history; severe infection; actively disseminated vascula blood coagulation.
- •Extended field radiotherapy within 4 weeks or limited field radiotherapy within 2 weeks prior to randomization. Subjects must have recovered from all therapy-related toxicities. The site of previous radiotherapy should have evidence of progressive disease if this is the only site of disease.
- •Pregnant or breast-feeding subjects. Women of childbearing potential must have a pregnancy test performed a maximum of 7 days before start of treatment, and a negative result must be documented before start of treatment.
- •Pleural effusion or ascites that causes respiratory compromise (≥Common Terminology Criteria for Adverse Events [CTCAE]) Grade 2 dyspnea)
- •Subjects unable to swallow oral medications
- •Known history of human immunodeficiency virus (HIV) infection
研究组 & 干预措施
combined use Raltitrexed and S-1
Experimental
Raltitrexed 3mg/m2 intravenously guttae, d1 and S-1,bid,po,d1-d14,every three weeks for a cycle.
BSA(body surface area) S-1 dosage <1.25 m2 80 mg/d
- 1.25m2 - <1.5 m2 100 mg/d
- 1.5 m2 120 mg/d
干预措施: Raltitrexed and S-1 (Drug)
结局指标
主要结局
Median disease progression free survival (mPFS) of Raltitrexed combined with S-1
时间窗: at least 24 months
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Rituximab to the Preparative Regimen of Etoposide and Total Body Irradiation in Acute Lymphoblastic LeukemiaLeukemiaNCT00427791M.D. Anderson Cancer Center23
已完成
2 期
PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) TumorsRectal CancerMetastatic Colorectal CancerColorectal CancerColon CancerNCT00819780Amgen285
已完成
2 期
Efficacy of Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With BevacizumabColorectal CancerNCT01442649UNICANCER133
已完成
2 期
A Randomised Placebo-Controlled Phase II Study of Continuous Maintenance Treatment With BIBF 1120 Following Chemotherapy in Patients With Relapsed Ovarian CancerOvarian NeoplasmsNCT00710762Boehringer Ingelheim89
进行中（未招募）
3 期
Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube CancerOvarian NeoplasmFallopian Tube NeoplasmsPeritoneal NeoplasmsNCT05257408Corcept Therapeutics381